Clinical efficacy and tolerability of Esketamine: a case series

INTRODUCTION: Esketamine is a novel antidepressant approved by the FDA in 2019 in the form of an intranasal spray, recommended for Treatment-Resistant Depression (TRD). The intranasal spray system appears to be more manageable than intravenous ketamine infusion. It contains ketamine’s S- isomer whic...

Descripción completa

Detalles Bibliográficos
Autores principales: Passani, C., Ragone, N., Congedo, C.M., Barbini, B., Zanardi, R., Cavallini, M.C., Colombo, C.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Cambridge University Press 2022
Materias:
Abstract
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9568066/
http://dx.doi.org/10.1192/j.eurpsy.2022.2294

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9568066/
http://dx.doi.org/10.1192/j.eurpsy.2022.2294

Ejemplares similares